Professor Li Min is an acclaimed scholar in the treatment of neurodegenerative diseases using Chinese medicine, currently serving as Dean of School of Chinese Medicine (SCM), Hong Kong Baptist University (HKBU). Joining Hong Kong HKBU in 2001, Professor Li currently holds several positions in SCM: Chair Professor of Chinese Medicine, Ma Pak Leung Endowed Professor in Innovative Neuromedicine, Director of Mr. & Mrs. Ko Chi Ming Centre for Parkinson’s Disease Research (CPDR), Golden Meditech Centre for NeuroRegeneration Sciences (GCNS) and HKBU Musketeers Foundation Traditional Chinese Medicine Research Institute for Age-related Diseases.

With over 40 years of clinical practice, teaching, and research in Chinese medicine, Professor Li specialises in the pharmacological studies and clinical treatment of neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and Amyotrophic Lateral Sclerosis (ALS) with Chinese medicine, as well as new drug development. She was mentored by Professor Deng Tietao, the first cohort of National Master of Traditional Chinese Medicine (TCM), and Professor Xiong Jibai, the third cohort of National Master of TCM. Professor Li was named the First Cohort of National Outstanding Female Chinese Medicine Practitioner in 2007, and received the HKBU President’s Award for Outstanding Performance in Teaching in 2013 and 2018, as well as the President’s Award for Outstanding Performance in Research Supervision in 2024.  She has consistently been ranked among the world’s top 2% scientists by Stanford University in recent years.

Professor Li’s research team has published about 200 high-level academic papers in international journals, including Nature Communications, Autophagy, Signal Transduction and Targeted Therapy, and Aging Cell. She has led a number of research projects funded by the National Natural Science Foundation of China and the Research Grants Council of Hong Kong. She has authored over 20 academic monographs and holds more than 20 patents from the United States, Europe, and China.

李敏，醫學博士，講座教授，馬百良創新神經藥物教授，博士生、博士後導師，為中醫內科學及中醫藥治療老年神經退行性疾病專家。李教授於2001年加入香港浸會大學，目前擔任中醫藥學院院長、高智明伉儷柏金遜症研究中心主任、金衛醫療神經再生研究中心主任以及香港浸會大學同心基金高齡疾病中醫藥研究所主任。

李教授從事中醫臨床、教學和研究工作逾四十年。目前主要從事老年神經退行性疾病（柏金遜症、阿爾茨海默病和肌萎縮側索硬化症等）的中醫臨床治療、中藥藥理研究與新藥研發。曾先後師從第一屆國醫大師鄧鐵濤教授和第三屆國醫大師熊繼柏教授。李教授榮獲 「全國首屆傑出女中醫師」稱號（2007年），獲得香港浸會大學傑出教學表現獎 （2013年, 2018年）及香港浸會大學傑出研究指導獎（2024年），近年亦位列斯坦福大學全球Top 2%科學家榜單。

李教授的科研團隊發表了包括“Nature Communications”, “Autophagy”, “Signal Transduction and Targeted Therapy” ,“Aging Cell” 等在內的國際高水平學術研究論文近200篇,主持國家自然科學基金、香港研究資助局研究基金等多項研究課題。出版學術專著20余部，並獲得了超過20項美國、歐洲及中國專利。

Professor Li’s key research area:

• The relationship between autophagy regulation and neurodegenerative diseases such as Parkinson’s Disease (PD), Alzheimer’s Disease (AD), and Amyotrophic Lateral Sclerosis (ALS).
• The application of Traditional Chinese Medicine (TCM) in the prevention and treatment of neurodegenerative diseases.
• The identification of molecular targets from TCM for novel drug discovery in neurodegeneration.
• Investigating the efficacy and safety of TCM for conditions such as AD and PD, through randomised controlled clinical trials, whilst also exploring the interaction between TCM and Western medicine.

李教授的主要研究領域：

• 自噬調控與神經退行性疾病（如柏金遜症、阿茲海默症、肌萎縮側索硬化症）的關係。
• 中醫藥在預防及治療神經退行性疾病中的應用。
• 從中醫藥中發現用於治療神經退行性疾病的新藥分子靶點。
• 通過隨機對照臨床試驗，研究中醫藥治療神經退行性疾病（如阿茲海默症、柏金遜症）的療效與安全性，並探索中西醫藥物的相互作用。